在线日韩日本国产亚洲丨少妇伦子伦情品无吗丨欧美性猛交xxxx免费看蜜桃丨精品人妻系列无码一区二区三区丨亚洲精品无码不卡在线播放

Your Good Partner in Biology Research

CRBN Antibody

  • 中文名稱:
    CRBN兔多克隆抗體
  • 貨號:
    CSB-PA842761ESR2HU
  • 規格:
    ¥3900
  • 圖片:
    • Western blot
      All lanes: CRBN antibody at 5.28µg/ml
      Lane 1: Mouse liver tissue
      Lane 2: A375 whole cell lysate
      Secondary
      Goat polyclonal to rabbit IgG at 1/10000 dilution
      Predicted band size: 51 kDa
      Observed band size: 51 kDa
    • Immunohistochemistry of paraffin-embedded human thyroid tissue using CSB-PA842761ESR2HU at dilution of 1:100
    • Immunohistochemistry of paraffin-embedded human heart tissue using CSB-PA842761ESR2HU at dilution of 1:100
  • 其他:

產品詳情

  • 產品描述:

    The CRBN polyclonal antibody is a high-quality and specific antibody that targets the CRBN protein. It is purified using antigen affinity chromatography. This CRBN antibody has been validated for use in various applications including ELISA, WB, and IHC. It is suitable for use with a wide range of samples from human and mouse. The immunogen used to generate the CRBN antibody is the recombinant human cereblon protein (1-280aa).

    The CRBN protein is known to be involved in various cellular processes, including protein degradation, cell cycle regulation, and DNA repair. The CRBN polyclonal antibody is a valuable research tool for studying the function of CRBN in these processes and for further understanding its role in human health and disease.

  • 產品名稱:
    Rabbit anti-Homo sapiens (Human) CRBN Polyclonal antibody
  • Uniprot No.:
  • 基因名:
  • 別名:
    CRBN; AD-006; Protein cereblon
  • 宿主:
    Rabbit
  • 反應種屬:
    Human, Mouse
  • 免疫原:
    Recombinant Human Protein cereblon protein (1-280AA)
  • 免疫原種屬:
    Homo sapiens (Human)
  • 標記方式:
    Non-conjugated
  • 克隆類型:
    Polyclonal
  • 抗體亞型:
    IgG
  • 純化方式:
    Antigen Affinity Purified
  • 濃度:
    It differs from different batches. Please contact us to confirm it.
  • 保存緩沖液:
    PBS with 0.02% sodium azide, 50% glycerol, pH7.3.
  • 產品提供形式:
    Liquid
  • 應用范圍:
    ELISA, WB, IHC
  • 推薦稀釋比:
    Application Recommended Dilution
    WB 1:1000-1:5000
    IHC 1:20-1:200
  • Protocols:
  • 儲存條件:
    Upon receipt, store at -20°C or -80°C. Avoid repeated freeze.
  • 貨期:
    Basically, we can dispatch the products out in 1-3 working days after receiving your orders. Delivery time maybe differs from different purchasing way or location, please kindly consult your local distributors for specific delivery time.
  • 用途:
    For Research Use Only. Not for use in diagnostic or therapeutic procedures.

產品評價

靶點詳情

  • 功能:
    Substrate recognition component of a DCX (DDB1-CUL4-X-box) E3 protein ligase complex that mediates the ubiquitination and subsequent proteasomal degradation of target proteins, such as MEIS2 (Probable). Normal degradation of key regulatory proteins is required for normal limb outgrowth and expression of the fibroblast growth factor FGF8. Maintains presynaptic glutamate release and consequently cognitive functions, such as memory and learning, by negatively regulating large-conductance calcium-activated potassium (BK) channels in excitatory neurons. Likely to function by regulating the assembly and neuronal surface expression of BK channels via its interaction with KCNT1. May also be involved in regulating anxiety-like behaviors via a BK channel-independent mechanism.
  • 基因功能參考文獻:
    1. mitochondrially expressed CRBN exhibited protease activity, and was induced by oxidative stress. PMID: 27417535
    2. We sequenced CRBN-thalidomide binding region in 38 thalidomide embryopathy individuals and 136 Brazilians without congenital anomalies, and performed in silico analyses. Eight variants were identified, seven intronic and one in 3'UTR. PMID: 27751757
    3. These findings thus contribute to a growing list of ID disorders caused by CRBN mutations, broaden the spectrum of phenotypes attributable to Autosomal-recessive non-syndromic intellectual disability (ARNS-ID)and provide new insight into genotype-phenotype correlations between CRBN mutations and the aetiology of ARNS-ID. PMID: 28143899
    4. CRBN expression is of prognostic value in MM patients ineligible for ASCT treated with thalidomide as an immunomodulatory drug. With low expression indicating a possible suboptimal treatment outcome, measurement of CRBN expression might serve as additional prognostic tool in the personalized treatment approach. PMID: 27618360
    5. Plasmablast differentiation, whether induced by BAFF or CD40L, is prevented by modulation of CRBN activity with CC-220, which induces degradation of the B cell differentiation factors Aiolos and Ikaros. Downregulation of these B cell differentiation processes by CC-220 modulation of CRBN provides a new therapeutic approach to treating B cell-mediated pathology in SLE. PMID: 28848067
    6. High CRBN expression is associated with multiple myeloma. PMID: 28017969
    7. CRBN negatively regulates TLR4 signaling via attenuation of TRAF6 and TAB2 ubiquitination. PMID: 27468689
    8. Compared with newly diagnosed multiple myeloma, an increased prevalence of mutations in the Ras pathway genes KRAS, NRAS, and/or BRAF (72%), as well as TP53 (26%), CRBN (12%), and CRBN pathway genes (10%) was observed. PMID: 27458004
    9. dual assay demonstrated superior Cereblon IHC measurement in MM samples compared with the single IHC assay using a published commercial rabbit polyclonal Cereblon antibody and could be used to explore the potential utility of Cereblon as a biomarker in the clinic PMID: 26186254
    10. IRF4 and CRBN polymorphisms affect risk and response to treatment in multiple myeloma PMID: 28083618
    11. overview of the current understanding of mechanism of action of Immunomodulatory drugs via CRBN and prospects for the development of new drugs that degrade protein of interest. PMID: 27460676
    12. 45.2 of multiple myeloma patients were CRBN(+). Among patients treated with thalidomide-based regimens, CRBN(+) patients showed a better treatment response than did CRBN-negative patients. There was no significant difference in survival outcomes between thalidomide- and bortezomib-based regimens in CRBN(+) patients. PMID: 27365142
    13. GS is acetylated at lysines 11 and 14, yielding a degron that is necessary and sufficient for binding and ubiquitylation by CRL4(CRBN) and degradation by the proteasome. PMID: 26990986
    14. Structural dynamics of the cereblon ligand binding domain. PMID: 26024445
    15. Our data are consistent with the idea that the CUL4A/B-DDB1-CRBN complex catalyses the polyubiquitination and thus controls the degradation of CLC-1 channels. PMID: 26021757
    16. Data suggest that cereblon (CRBN) expression in peripheral blood chronic lymphocytic leukemia (CLL) cells is independent of prognostic factors and may be considered a potential biomarker. PMID: 24925210
    17. High levels of full-length CRBN mRNA in lower risk 5q deletion patients are necessary for the efficacy of lenalidomide. PMID: 25284710
    18. A copy number gain of CRBN gene might be responsible for developmental delay/intellectual disability. PMID: 25858704
    19. Although abnormal CRBN function may be associated with intellectual disability disease onset, its cellular mechanism is still unclear. Here, we examine the role of CRBN in aggresome formation and cytoprotection. PMID: 26188093
    20. Studied the protein cereblon , which has been recently indentified as a primary target of thalidomide and its C-terminal part as responsible for binding thalidomide within a domain carrying several invariant cysteine and tryptophan residues. PMID: 25569776
    21. The study presents the crystal structure of human CRBN bound to DDB1 and the drug lenalidomide. PMID: 25108355
    22. structures of the DDB1-CRBN complex bound to thalidomide, lenalidomide and pomalidomide PMID: 25043012
    23. CRBN expression in bone marrow myeloma cells is associated with superior treatment response to lenalidomide in refractory myeloma and thalidomide/dexamethasone in new patients. CRBN is a crucial factor for the anti-MM effect of immunomodulators. PMID: 24687382
    24. CRBN expression may provide a biomarker to predict response to Immunomodulatory drugs in patients with MM and its high expression can serve as a marker of good prognosis. PMID: 24118365
    25. CRBN and IRF4 have been shown to be associated with response to lenalidomide in patients, these findings do not translate back to HMCLs, which could be attributable to factors present in the bone marrow microenvironment. PMID: 23992230
    26. In the three intrinsically IMiD-resistant cell lines that clearly express detectable levels of cereblon, the absence of CRBN and DDB1 mutations suggest that potential cereblon-independent mechanisms of resistance exist PMID: 24166296
    27. Presents a molecular model in which drug binding to cereblon results in the interaction of Ikaros and Aiolos to CRL4(CRBN) , leading to their ubiquitination, subsequent proteasomal degradation and T cell activation. PMID: 24328678
    28. Data indicate that low cereblon (CRBN) expression can predict resistance to immunomodulatory drug (IMiD monotherapy and is a predictive biomarker for survival outcomes. PMID: 24129344
    29. Findings suggest an approach for the treatment of mental retardation associated with cereblon nonsense mutation. PMID: 23983124
    30. We investigated the role of CRBN in response to lenalidomide in myelodysplastic syndrome infants without chromosome 5 deletion. PMID: 23434730
    31. We conclude that CRBN expression may be associated with the clinical efficacy of thalidomide. PMID: 23233657
    32. These findings suggest that CRBN may modulate proteasome activity by directly interacting with the beta7 subunit. PMID: 23026050
    33. Data show that in a cereblon-dependent fashion, lenalidomide downregulates IRF4 and SPIB, transcription factors that together prevent IFNbeta production. PMID: 22698399
    34. CRBN is an essential requirement for immunoregulatory drugs activity and a possible biomarker for the clinical assessment of antimyeloma efficacy. PMID: 21860026
    35. CRBN directly interacts with the alpha1 subunit of AMP-activated protein kinase (AMPK alpha1) and inhibits the activation of AMPK activation. PMID: 21232561
    36. The results suggest that mutCRBN may cause ARNSID by disrupting the developmental regulation of BK(Ca) in brain regions that are critical for memory and learning. PMID: 20131966
    37. A nonsense mutation causing a premature stop codon in CRBN was found in a large kindred with mild mental retardation. ATP-dependent degradation of proteins may play a role in memory and learning. PMID: 15557513
    38. This may suggest new functions of CRBN in cell nucleolus besides its mitochondria protease activity in cytoplasm. PMID: 17380424
    39. Nonsense mutation (R419X) CRBN disturbs the development of adult brain BK(Ca) isoforms. These changes are predicted to result in BK(Ca) channels with a higher intracellular Ca(2+) sensitivity, faster activation, and slower deactivation kinetics. PMID: 18414909

    顯示更多

    收起更多

  • 相關疾病:
    Mental retardation, autosomal recessive 2A (MRT2A)
  • 亞細胞定位:
    Cytoplasm. Nucleus. Membrane; Peripheral membrane protein.
  • 蛋白家族:
    CRBN family
  • 組織特異性:
    Widely expressed. Highly expressed in brain.
  • 數據庫鏈接:

    HGNC: 30185

    OMIM: 607417

    KEGG: hsa:51185

    STRING: 9606.ENSP00000231948

    UniGene: Hs.18925



主站蜘蛛池模板: 永久免费观看美女裸体视频的网站| 少妇粗大进出白浆嘿嘿视频| 少妇高潮喷水久久久久久久久久| 三级4级全黄60分钟| 少妇做爰免费视频网站| 国产午夜亚洲精品不卡| 成年片色大黄全免费软件到| 真实国产精品vr专区| 亚洲国产区男人本色vr| mm1313亚洲国产精品无码试看| 40岁成熟女人牲交片20分钟| 国产精品久久久久7777| 国产影片av级毛片特别刺激| 亚洲色偷偷偷网站色偷一区| 伊人婷婷六月狠狠狠去| 亚洲色大成网站www国产| 一区二区三区在线 | 网站| 夜色福利院在线观看免费| 蜜桃av亚洲精品一区二区| 国产传媒精品1区2区3区 | 国产精品久久久久久52avav| 亚洲色欲色欲www| 国内精品久久久人妻中文字幕| 中文字幕无码专区一va亚洲v专区在线| 亚洲精品午夜无码电影网| 在线中文字幕亚洲日韩2020| 中国妇女做爰视频| 久久综合给合久久狠狠狠97色69 | 日韩综合无码一区二区| 亚洲欧美日韩成人综合一区| 啪啪激情婷婷久久婷婷色五月| 色婷婷五月综合色啪网| 好爽…又高潮了毛片免费看| 成av人电影在线观看| 熟妇玩小男视频在线| 萝卜视频高清免费视频日本| 亚洲电影在线观看| 久久精品国产精品亚洲下载 | 国产亚洲精品自在久久| 免费裸体黄网站18禁免费| 欧美人与动性xxxxbbbb|